J9037 Injection, belantamab mafodotin-blmf, 0.5 mg

Short descriptor: Inj belantamab mafodot blmf

⚠ Terminated HCPCS Level II 2026
Terminated Code
J9037 was terminated as of 2025-03-31 and should not be reported for dates of service after that date. This page is retained for historical reference.
Open J9037 in the app →

Look up J9037 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.

J9037 is the HCPCS Level II code for Injection, belantamab mafodotin-blmf, 0.5 mg (2026). It belongs to Section J — Drugs Administered Other Than Oral Method. Under Medicare, its coverage status is: Carrier judgment. Part B pricing methodology: Drugs.

Classification & CMS Attributes

Medicare Coverage
Carrier judgment (code C)
Part B Pricing
Drugs (indicator 51)
Type of Service
Medical care
Effective Date
2025-04-01
Termination Date
2025-03-31
2026 Maintenance
No change this year

Drug Details

Drug / Substance
belantamab mafodotin-blmf
Dose / Unit
0.5 mg
Route
Injection

See the full HCPCS Table of Drugs (J-codes).

References

Cite This Page

Reference J9037 with the canonical source and edition:

J9037 — Injection, belantamab mafodotin-blmf, 0.5 mg. ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/J9037

Canonical URL: https://icd10codingpro.com/hcpcs-codes/J9037

Related Codes in Section J

Browse all HCPCS Level II sections →
Reviewed by Prajwal Shrestha, CPC, CRC
Certified Professional Coder (CPC) and Certified Risk Adjustment Coder (CRC) · AAPC Member ID 01997614 · About · Editorial policy · Content last reviewed: 2026-01-01

Get HCC Mappings, Clinical Summaries, and More

Access premium features including HCC risk adjustment, FDA drug indications, AI coding assistant, and comprehensive clinical context.

Start Free Trial